UPDATED 18:45 PT – Friday 20. November 2020
The FDA issued an emergency use approval for a drug combination with coronavirus for the treatment of moderate and severely ill patients.
FDA Commissioner Dr. Stephen M. Hahn said this action demonstrates the agency’s firm efforts to make potential coronavirus treatments available in a timely manner.
On Thursday, the FDA approved the mixture of ‘remdesevir’ and rheumatoid arthritis ‘baricitinib’. This came after studies showed that the drug combination shortened the recovery time for COVID-19 to approx. one week.
As of today, 289 tests are approved by the FDA under EUAs; these include 224 molecular tests, 58 antibody tests and 7 antigen tests.
– US FDA (@US_FDA) November 21, 2020
According to a double-blind trial, the combination also increased the chances of survival by 35 percent compared to patients who only took ‘remdesivir’.
The FDA has approved emergency use approval of the arthritis medicine baricitinib to be used in combination with strapsivir for the treatment of hospitalized adults and children with suspected or confirmed COVID-19. https://t.co/GVSGz9mdRx pic.twitter.com/esKvNvIg8x
– WebMD (@WebMD) November 20, 2020